Enhanced antitumour immunity by combined use of temozolomide and TAT-survivin pulsed dendritic cells in a murine glioma
/in Glioblastoma, International Publications /von 2007-07-20 / Immunology 2007 Dec;122(4):615-22Development of vaccines for high-risk ductal carcinoma in situ of the breast
/in Breast Cancer, International Publications /von 2007-07-15 / Cancer Res. 2007 Jul;67(14):6531-4Antigen loading of dendritic cells with apoptotic tumor cell-preparations is superior to that using necrotic cells or tumor lysates
/in Breast Cancer, International Publications /von 2007-07-01 / Anticancer Res. 2007 Jul-Aug;27(4B):2121-9[State of the art about new therapeutic vaccines in prostate cancer: dendritic cells, engineered tumor cells and recombinant virus]
/in International Publications, Prostate Cancer /von 2007-07-01 / Bull Cancer 2007 Jul;94(7 Suppl):F69-76
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution